The circuit
Butyrate is a short-chain fatty acid produced by gut bacteria from dietary fiber. It is the primary endogenous agonist of GPR109A in the colon. When gut bacteria produce sufficient butyrate, GPR109A signaling maintains immune tolerance in the gut — promoting regulatory T cells, suppressing inflammatory cytokines, and maintaining epithelial barrier integrity.
When this circuit breaks — through dysbiosis, antibiotic use, poor diet, or chronic illness — butyrate production drops, GPR109A signaling weakens, and gut immune regulation fails. The resulting inflammation further damages the microbiome, creating a self-reinforcing cycle.
Nicotinic acid is an exogenous GPR109A agonist. It can activate the same receptor that butyrate would, bypassing the broken microbiome entirely.
Evidence for the circuit
Activation of GPR109A by both niacin and butyrate suppresses colonic inflammation and carcinogenesis in multiple studies. The mechanism requires GPR109A — knockout models show no benefit.
Deficient butyrate-producing capacity in the gut microbiome is documented in ME/CFS patients and is associated with fatigue symptoms. This connects microbiome dysfunction to a specific immune-mediated condition through a measurable metabolite.
Bacterial PNCa (nicotinic acid-converting enzyme) improves diet-induced fatty liver in mice by enabling the transition from nicotinamide to nicotinic acid — showing that the gut microbiome itself participates in niacin metabolism and GPR109A signaling.
The melatonin connection
Gut melatonin — produced by enterochromaffin cells in quantities far exceeding pineal production — is a potent modulator of gut immune function. Gut dysbiosis dysregulates central and systemic homeostasis via decreased melatonin and suboptimal mitochondrial functioning.
Melatonin alleviates titanium nanoparticle-induced osteolysis via activation of the butyrate/GPR109A signaling pathway, directly linking melatonin to the same receptor that nicotinic acid activates.
TRPV4 stimulation induces melatonin secretion, and nicotinic acid is a common regulator of heat-sensing TRPV1-4 ion channels. This creates an unexpected connection: nicotinic acid may influence gut melatonin production through TRPV channel regulation.
The COVID-19 intersection
Intestinal flora was identified as a potential strategy against SARS-CoV-2 infection, with butyrate-producing bacteria and GPR109A signaling implicated in immune defense. Network pharmacology analyses identify intersection genes of niacin and COVID-19 as potential therapeutic targets.
Coronavirus infection depletes NAD+ through PARP dysregulation, while simultaneously disrupting the gut microbiome — attacking both sides of the niacin-GPR109A-immune axis simultaneously.
What remains unknown
- Dose to substitute for butyrate: How much oral nicotinic acid produces equivalent GPR109A activation in the colon compared to endogenous butyrate production?
- Microbiome restoration: Does nicotinic acid supplementation help restore butyrate-producing bacteria, or does it merely substitute for their absence?
- Route matters: The ulcerative colitis study used niacin enemas (direct colonic application). Whether oral niacin reaches the colon in sufficient concentration for local GPR109A activation is unclear.
- ME/CFS connection: The butyrate deficiency in ME/CFS is documented, but whether nicotinic acid supplementation improves ME/CFS symptoms through GPR109A compensation has not been tested.